美国食品和药物管理局对远程医疗公司发出100多条警告, FDA issues 100+ warnings to telehealth firms over false claims about unapproved weight-loss drugs.

林业发展局向包括Hims & Hers在内的远程保健和制药公司发出了100多封警告信,要求它们取消关于未经批准的重量损失药物的“虚假和误导”说法。 The FDA has issued over 100 warning letters to telehealth and drug companies, including Hims & Hers, demanding they remove "false and misleading" claims about unapproved weight-loss drugs. 该机构以在线平台为目标,宣传诸如Wegovy和Ozempic等经林业发展局批准的药物的复合版本,强调这些配方未经林业发展局审查或批准。 The agency targeted online platforms promoting compounded versions of FDA-approved medications like Wegovy and Ozempic, stressing these formulations are not reviewed or approved by the FDA. 这是FDA首次直接挑战这些公司, 使用"停止和放弃"语言, 作为特朗普政府在数字平台上监管药品广告的更广泛努力的一部分. This marks the first time the FDA has directly challenged such companies, using "cease and desist" language, as part of a broader Trump administration effort to regulate pharmaceutical advertising across digital platforms.